Purple Biotech has released more promising interim findings from its randomized Phase 2 study on pancreatic cancer with CM24. These results provide insights into a potential biomarker that could predict an improvement in overall survival.

June 27, 2024

XLV Health Care
PPBT

New data suggests that baseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs…

Read More: https://www.globenewswire.com/news-release/2024/06/27/2905110/0/en/Purple-Biotech-Reports-Additional-Positive-Interim-Results-from-its-Randomized-Phase-2-Pancreatic-Cancer-Study-with-CM24-Regarding-a-Potential-Predictive-Biomarker-for-Overall-Surv.html

Sector Investors News and Insights

Purple Biotech has released more promising interim findings from its randomized Phase 2 study on pancreatic cancer with CM24. These results provide insights into a potential biomarker that could predict an improvement in overall survival.

© 2025 ETF Sector

Sector Investors News and Insights

Purple Biotech has released more promising interim findings from its randomized Phase 2 study on pancreatic cancer with CM24. These results provide insights into a potential biomarker that could predict an improvement in overall survival.

© 2025 ETF Sector

Subscribe to our Newsletter